Denali Therapeutics Inc. Lessor, Operating Lease, Payment to be Received, Year One
Denali Therapeutics Inc. (DNLI) had Lessor, Operating Lease, Payment to be Received, Year One of $3.10 million as of 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths · last filed 2023-02-27
- 2022-12-31: Lessor, Operating Lease, Payment to be Received, Year One $3.10M.
- 2022-09-30: Lessor, Operating Lease, Payment to be Received, Year One $3.10M.
- 2022-06-30: Lessor, Operating Lease, Payment to be Received, Year One $3.10M.
- 2022-03-31: Lessor, Operating Lease, Payment to be Received, Year One $3.10M.
| Period end | Lessor, Operating Lease, Payment to be Received, Year One |
|---|---|
| 2022-12-31 | $3.10M 10-K · filed 2023-02-27 |
| 2022-09-30 | $3.10M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $3.10M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.10M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.01M 10-K · filed 2022-02-28 |
| 2021-09-30 | $3.01M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.01M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $3.01M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $2.92M 10-K · filed 2021-02-26 |
| 2020-09-30 | $2.92M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.92M 10-Q · filed 2020-08-07 |
| 2019-12-31 | $2.84M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |